Esperion Therapeutics Inc. (NASDAQ: ESPR) has seen a decline in its stock price by -3.83 in relation to its previous close of 1.96. However, the company has experienced a 2.45% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-19 that Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy rating for Esperion Therapeutics, Inc. based on current execution and expanding international scope.
Is It Worth Investing in Esperion Therapeutics Inc. (NASDAQ: ESPR) Right Now?
Moreover, the 36-month beta value for ESPR is 1.02. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ESPR is 187.38M and currently, short sellers hold a 20.35% of that float. On August 19, 2024, ESPR’s average trading volume was 7.32M shares.
ESPR’s Market Performance
ESPR stock saw a decrease of 2.45% in the past week, with a monthly decline of -21.13% and a quarterly a decrease of -20.13%. The volatility ratio for the week is 7.43%, and the volatility levels for the last 30 days are 7.23% for Esperion Therapeutics Inc. (ESPR). The simple moving average for the last 20 days is -11.77% for ESPR stock, with a simple moving average of -13.78% for the last 200 days.
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with BofA Securities repeating the rating for ESPR by listing it as a “Underperform.” The predicted price for ESPR in the upcoming period, according to BofA Securities is $2.50 based on the research report published on June 20, 2024 of the current year 2024.
ESPR Trading at -20.18% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.56% of loss for the given period.
Volatility was left at 7.23%, however, over the last 30 days, the volatility rate increased by 7.43%, as shares sank -21.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.08% lower at present.
During the last 5 trading sessions, ESPR rose by +3.26%, which changed the moving average for the period of 200-days by +129.25% in comparison to the 20-day moving average, which settled at $2.1110. In addition, Esperion Therapeutics Inc. saw -36.96% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Warren Eric, who sale 108 shares at the price of $2.59 back on Jul 17 ’24. After this action, Warren Eric now owns 165,478 shares of Esperion Therapeutics Inc., valued at $279 using the latest closing price.
Foody Joanne M., the Chief Medical Officer of Esperion Therapeutics Inc., sale 917 shares at $2.60 during a trade that took place back on Jul 17 ’24, which means that Foody Joanne M. is holding 272,862 shares at $2,383 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.82 for the gross margin
The net margin for Esperion Therapeutics Inc. stands at -0.35. The total capital return value is set at 0.03.
Based on Esperion Therapeutics Inc. (ESPR), the company’s capital structure generated 2.65 points at debt to capital in total, while cash flow to debt ratio is standing at -0.05. The debt to equity ratio resting at -1.61. The interest coverage ratio of the stock is -0.18.
Currently, EBITDA for the company is -155.4 million with net debt to EBITDA at 74.0. When we switch over and look at the enterprise to sales, we see a ratio of 2.61. The receivables turnover for the company is 4.6for trailing twelve months and the total asset turnover is 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.97.
Conclusion
To wrap up, the performance of Esperion Therapeutics Inc. (ESPR) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
